Clinical Trial Update: Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase II trial completed evaluating the radiosensitizing effect of ZARNESTRA in patients with glioblastoma multiforme.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• ZARNESTRA

Snippet

Sponsor: Institut Claudius Regaud | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED